Volume 14, Issue 1 ( March 2022 2022)                   Iranian Journal of Blood and Cancer 2022, 14(1): 33-36 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Suwanto D, Aminuddin M, Mulia E P B. Complex Arterial and Venous Thrombosis in Polycythemia Vera: what Does Leukocytosis Predict?. Iranian Journal of Blood and Cancer 2022; 14 (1) :33-36
URL: http://ijbc.ir/article-1-1104-en.html
1- Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Hospital, Surabaya, Indonesia
2- Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Hospital, Surabaya, Indonesia , maminuddincardio@gmail.com
Abstract:   (1537 Views)

Thromboembolic events represent the main cause of morbidity and mortality in patients with polycythemia vera. Leukocytosis has been identified as an important risk factor for development of vascular thrombosis. A 47-year-old woman with polycythemia vera presented with pain and swelling in her right calf. She was scheduled to receive anagrelide which was effective on polycythemia and thrombocytosis, but leukocytosis persisted. She was diagnosed with thrombosis in right popliteal vein and left common femoral vein by duplex ultrasonography. We suggested a role for leukocytosis in inducing thrombotic phenomenon in our patient with polycythemia vera.

Full-Text [PDF 1207 kb]   (575 Downloads)    
: Case report | Subject: Adults Hematology & Oncology
Received: 2021/01/3 | Accepted: 2022/02/16 | Published: 2022/04/30

References
1. Landolfi R, Di Gennaro L, Barbui T, Stefano VD, Finazzi G, Marfisi R, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2006;109(6):2446-52. [DOI:10.1182/blood-2006-08-042515]
2. Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 2018;8(1):3. [DOI:10.1038/s41408-017-0042-7]
3. Spivak JL, Dc W. Polycythemia vera : myths , mechanisms , and management review article Polycythemia vera: myths, mechanisms , and management. Blood. 2012;100(13):4272-90. [DOI:10.1182/blood-2001-12-0349]
4. Marchioli R, Finazzi G, Specchia G, Masciulli A, Mennitto MR, Barbui T. The CYTO-PV: A LargeScale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera. Thrombosis. 2011;2011:1-9. [DOI:10.1155/2011/794240]
5. Raedler LA. Diagnosis and management of polycythemia vera. Semin Thromb Hemost. 2014;32(3):37-47. doi:10.1055/s-2006-939438. [DOI:10.1055/s-2006-939438]
6. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33(5):523-30. [DOI:10.1016/j.exphem.2005.01.015]
7. Falanga A, Marchetti M, Evangelista V, Manarini S, Oldani E, Giovanelli S, et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colonystimulating factor. Blood. 1999;93(8):2506-14. [DOI:10.1182/blood.V93.8.2506]
8. Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res. 2002;108(2-3):139-45. [DOI:10.1016/S0049-3848(02)00354-7]
9. Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet- leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol. 2001;66(3):143-51. [DOI:10.1034/j.1600-0609.2001.00359.x]
10. Cerletti C, Tamburrelli C, Izzi B, Gianfagna F, de Gaetano G. Platelet-leukocyte interactions in thrombosis. Thromb Res. 2012;129(3):263-6. [DOI:10.1016/j.thromres.2011.10.010]
11. Landolfi R, Nicolazzi MA, Porfidia A, Di Gennaro L. Polycythemia vera. Intern Emerg Med. 2010;5(5):375- 84. [DOI:10.1007/s11739-010-0369-6]
12. Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality. Arterioscler Thromb Vasc Biol. 2005;25(4):658-70. [DOI:10.1161/01.ATV.0000156877.94472.a5]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb